AllDocs -> cancers

Thyroid cancer The thyroid gland is in the throat, below the larynx (Adam’s apple). It comprises two lobes that sit on either side of the windpipe, joined at the front by an isthmus. The thyroid gland secretes hormones that regulate many metabolic processes, such as growth and energy expenditure. Around one out of every 1,000 people will be affected by thyroid cancer , with women slightly more susceptible than men. Risk factors include chronic goitre, family history, gender and exposure to radiation, particularly if the doses were given specifically to the head and neck. In the 1950s, radiation therapy was often used to treat problems of the adenoids and tonsils. Nuclear fallout is also associated with thyroid cancer . There are different types of thyroid cancer , categorised by malignancy, growth rate and the type of cells affected. Recovery depends on various ...

To: Family Physicians Caring for Adults with Differentiated Thyroid Cancer Adults with differentiated thyroid cancer typically have a very good clinical outcome, but there is a risk of late recurrence and death which mandates lifelong follow up. Since thyroid cancer is typically an indolent tumour, recurrences may not manifest for many years (or even decades) after initial diagnosis and treatment. Your patient is felt to be at relatively low risk for future problems related to thyroid cancer and is now being discharged back to your care for continued management and follow up. The following is generally considered a typical follow up plan: 1. Careful re-examination of the neck at least once per year. Rationale: Lymphadenopathy may herald a local/regional recurrence, and is the most common site for recurrence (followed by lung). 2. Annual reassessment of serum TSH for adjustment of ...

INFORMATION REQUIRED BY CCMB REFERRAL CENTRE— THYROID CANCER 1. GENERAL INFORMATION Key: shaded text – denotes required information * (asterisk) – denotes optional information Please send results/reports if done. - Demographic information (New Patient Referral Form) - Letter of referral - History and physical - Co-existing medical conditions - Allergies - Previous malignancy information (diagnosis and previous treatment ) 2. PATHOLOGY REPORTS Attach copy of ORIGINAL REPORT(S): - ALL tissue biopsy report(s) (FNA, core biopsy, excisional biopsy) - Pathology from definitive surgical procedure, if applicable * 3. OPERATIVE REPORTS - Reports from any surgical biopsy procedure(s) - Reports from definitive surgical procedure, if applicable * 4. IMAGING REPORTS ...

Chapter 33: Thyroid cancer 315 Thyroid cancer 7K\URLGFDQFHULVUHODWLYHO\XQFRPPRQ SDUWLFXODUO\DPRQJPDOHV ,QWKHODWH VRQ DYHUDJH QHZFDVHVDPRQJPDOHVDQG DPRQJIHPDOHVZHUHUHJLVWHUHGHDFK\HDU DQG VHYHQDQG GHDWKVZHUHUHFRUGHGDPRQJPDOHVDQGIHPDOHVUHVSHFWLYHO\ 7KHVHUHSUHVHQW OHVVWKDQ RIDOOUHJLVWUDWLRQVDQG RIDOOFDQFHUGHDWKV 7KH LQFLGHQFH RI WK\URLG FDQFHU KDV KRZHYHU EHHQ ULVLQJ VWHDGLO\ VLQFH ZKHQ UHOLDEOH GDWD ILUVW EHFDPH DYDLODEOH IRU WKLV FDQFHU IURP DQ DYHUDJH DQQXDO DJH VWDQGDUGLVHGLQFLGHQFHUDWHRI SHU WR SHU DPRQJPDOHV DQGIURP SHU WR SHU DPRQJIHPDOHV E\ 2YHUWKHVDPHSHULRG WKH DYHUDJHDQQXDODJHVWDQGDUGLVHGPRUWDOLW\UDWHKDVVKRZQDVWHDG\GRZQZDUGWUHQG IURP SHU WR SHU DPRQJPDOHV DQGIURP SHU WR SHU DPRQJIHPDOHV 7KH FRQWUDVWLQJ LQFLGHQFH DQG PRUWDOLW\ WUHQGV SURYLGH HYLGHQFH RI FRQWLQXLQJ LPSURYHPHQWV LQ WK\URLG FDQFHU VXUYLYDO ZKLFK LV QRZ FRQVLGHUHG WR EH YHU\ KLJK FRPSDUHGZLWKPDQ\RWKHUFDQFHUV ...

30 Cloning of the genes for non-medullary thyroid cancer : Methods and advances Karmen Stankov 1 , Giovanni Romeo 2 ABSTRACT In last ten years, significant advances have occurred in thyroid endocrinology, as a consequence of the generalized use of molecular biology techniques. New genes involved in the development of thyroid can- cer have been identified, which had a great impact on our understanding of thyroid cancer predisposi- tion. All cancers are genetic in origin because they arise from mutations in a single somatic cell, but the genetic changes in sporadic cancers are confined to a particular tissue. In inherited cancers, a predis- posing mutation is present in all somatic cells and in the germ line, which enables the transmission of risk to the next generation. Cancer genetics offers a model of how information on the genetics of inher- ited cancers could affect ...

Reference Section a report by Er nest L Mazzaferri , MD , MACP President-Elect, American Thyroid Association (ATA) Types and Basic Biologic Features of Thyroid Cancer Differentiated Thyroid Cancer Thyroid cancer is the most common endocrine malignancy. It comprises several distinct tumor types; including papillary thyroid cancer (PTC); follicular thyroid cancer (FTC); and Hürthle cell thyroid cancer (HTC), which are tumors of the thyroid follicular cell derived from the embryonic foregut. They ordinarily concentrate iodine and sometimes synthesize and secrete thyroid hormone, and for this reason are collectively referred to as differentiated thyroid cancer (DTC).The three tumor types represent 80%, 11%, and 3% of all thyroid cancers, respectively, and have 10-year mortality ...

Follow-up Testing for Thyroid Cancer Patients To assess whether all thyroid cells have been destroyed, two principal diagnostic tests are used, a total body scan, and a thyroglobulin blood test. These tests need to be done periodically, and it is necessary to have the levels of TSH ( thyroid stimulating hormone) elevated during the test, which can be achieved either by withdrawing a patient from thyroid hormone, or with the use of recombinant TSH. On the day that the scan is done, a blood test for TSH and the thyroglobulin protein should also be obtained. As it can take a few days for the test results to become available, patients who have been withdrawn from thyroid hormone may go back on T3 (Cytomel) while waiting for the all results to come back, whereas patients who received recombinant TSH simply continue on their thyroxine. The thyroglobulin and TSH blood tests will be ordered in ...

D ATA S HEET Rev 061406C Thyroid Cancer Marker (Clone 373E1) Mouse Monoclonal Antibody Cat. #MS-1914-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml Supernatant) Cat. #MS-1914-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining) 47777 Warm Springs Blvd. Fremont CA 94539 USA Tel: (800) 828-1628 Fax: (510) 991-2826 Email: labvision@labvision.com Website: www.labvision.com Description: Papillary carcinoma is by far the most frequent malignant tumor of the thyroid with a threefold prevelance in females. Studies have shown that 100% of malignant thyroid lesions were found to contain the keratan sulfate (KS) bearing molecules, while these were virtually absent from benign tissues and other thyroid tumors, with the exception of 21% of follicular carcinoma cases analyzed 1 . Clone ...

Update on thyroid cancer surveillance and management of recurrent disease July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David Geffen School of Medicine at UCLA www.endocrinesurgery.ucla.edu Minimally invasive thyroid surgery Page 2 Differentiated thyroid cancer • Prognosis highly favorable • Overall survival: papillary 98%, follicular 92% • Median age at diagnosis 45 • 25% lifetime recurrence risk • Increased mortality assoc. with recurrence • PTC metasta...

THYROID CANCER - All Sections THYROID CANCER What Is Cancer ? Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer , they all start because of out-of-control growth of abnormal cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, cells in most parts of the body divide only to replace worn-out or dying cells and to repair injuries. Because cancer cells continue to grow and divide, they are different from normal cells. Instead of dying, they outlive normal cells and continue to form new abnormal cells. Cancer cells often travel to other parts of the body where they begin to grow and replace normal tissue. This process, called metastasis, occurs as the cancer cells get into the bloodstream ...

Page 2 Mortality trends in England; ICD9 (193), ICD10 (C73); File: Sepho 96-04 V2 Thyroid cancer in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for thyroid cancer in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

Radiation Therapy & Thyroid Cancer Page 2 Radiation Therapy • External beam * • Intracavitary/brachytherapy • Interstitial • Radiopharmaceutical * Page 3 External Beam • Different machines for different tumour locations • Usually a series of treatments - multiple fractions per course • Each fraction takes only minutes Page 4 Systemic Radiotherapy • Radioactive iodine p.o.* • Radioactive phosporous intra-peritoneal • Labeled radioactive antibodies - undergoing research Page 5 Radioactive Iodine I131 • Beta particles mostly • Physical half life 8 days • Biologic half life varies: 4 days to 17 hours • Dose given varies from 30 mCi to 200 mCi • ...

www.ljm.org.ly Libyan J Med, AOP:060514 1 Cite this article as: Libyan J Med, AOP:060514 (published 6 June 2006) Update on epidemiology classification, and management of thyroid cancer ABC article Heitham Gheriani, MD, FRCS (I), FRCS (Ed) HNS Department, St Vincent University Hospital, Elm Park, Dublin 4, Ireland. Received for publication on 23 Jan 2006. Accepted in revised form on 03 May 2006. INTRODUCTION Thyroid cancer represents approximately 0.5–1% of all human malignancy 1 . In the UK the incidence of thyroid cancer is 2-3 per 100,000 populations 2 . In geographical areas of low iodine intake and in areas exposed to nuclear disasters the incidence of thyroid cancer is higher. Benign thyroid conditions are much more common. In the UK approximately 8 % of the population ...

Steven Waguespack, MD Sam Wells, MD Julie Ross, PhD Archie Bleyer, MD Chapter 12 Thyroid Cancer Cancer in 15- to 29-Year-Olds in the United States Page 2 CHAPTER 12 THYROID CANCER SEER AYA Monograph 144 National Cancer Institute HIGHLIGHTS Incidence • In the United States from 1975 to 2000, thyroid cancer accounted for about 10% of all malignancies diagnosed in individuals 15 to 29 years of age and was the 4th most common cancer in this age group. • Nearly 2,400 individuals 15 to 29 years of age were diagnosed with a malignant thyroid neoplasm in the U.S. during the year 2000. • Thyroid ...

Thyrogen is a registered trademark of Genzyme Corporation. Copyright© 2005, Genzyme Corporation All rights reserved. Printed in USA. THY/US/P092/11/05 Genzyme Corporation 500 Kendall Street Cambridge, MA 02142 www.genzyme.com Page 2 Where is the thyroid gland and what does it do? Your thyroid is a gland located at the base of your neck, just below your Adam’s apple. It is shaped like a butterfly. One wing, or lobe, of your thyroid gland lies on each side of your windpipe. The purpose of your thyroid gland is to produce, store, and release thyroid hormones into your bloodstream. These hormones, called T3 and T4, affect almost every cell in your body and help control your body’s metabolism. If you have too little thyroid hormone in your blood, your body slows down. This condition ...

Surveillance Guidelines Using Recombinant Human TSH in Well-Differentiated Thyroid Cancer Management 1 A suggested management algorithm illustrating the surveillance of low-risk well-differentiated thyroid cancer patients, including the use of Thyrogen to complement existing standards of care, is shown below. Figure 1. Algorithm for follow-up. An experienced endocrinologist or radiologist should perform neck ultrasonography. Negative RxWBS implies that the tumor does not concentrate 131 I or is too small to be imaged on RxWBS and that further studies are necessary. • This algorithm applies only to patients with papillary thyroid carcinoma * and low-grade follicular thyroid carcinoma ? • Initial therapy is assumed to be total thyroidectomy and 131 I remnant ablation • Tg on thyroid hormone therapy assumes ...

Chapter 18b. Thyroid Cancer Presentation of this chapter is supported in part by Genzyme , the makers of rhTSH (THY- ROGEN) Incidence and Distribution The annual incidence of thyroid cancer varies considerably in different registries, ranging from 1.2-2.6 per 100,000 individuals in men and from 2.0-3.8 per 100,000 in women (92, 93). It is particularly elevated in Iceland and Hawaii, being nearly two times higher than in North European countries, Canada and the USA. In Hawaii, the incidence rate of thyroid cancer in each ethnic group is higher than that registered in their country of origin (94), and it is particularly common among Chinese males and Filipino females. Most of the differences are probably due to ethnic or environ- mental factors (such as spontaneous background radiation) or dietary habits (95), but different standards of medical expertise and health care may also play a role ...

Department of Medical Oncology Chemotherapy Protocols 3 rd Edition 105 Protocol: Cisplatin/Doxorubicin Indications: Thyroid Cancer Schedule: Drug Dose iv/infusion/oral q Doxorubicin 60mg/m 2 iv Day 1 Cisplatin 60mg/m 2 1L N. Saline/2hrs Days 1 & 2 Cycle frequency: Every four weeks Total number of cycles: 6 (2 before RT) Dose modifications: Discuss with Consultant Administration and safety: • Anti-emetic group – High • Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L • Ensure adequate renal function • Pre & post-hydration, mannitol, potassium & magnesium Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea & vomiting, mucositis, alopecia, amenorrhoea, ...

Radioiodine (I131)Treatment for Thyroid Cancer Patient Information Page 1 of 6 The Northern Centre for Cancer Treatment Radioiodine (I131) Treatment for Thyroid Cancer This information sheet has been designed to provide you with some useful information about your admission to the Northern Centre for Cancer Treatment for I131treatment. This leaflet explains: Where you will have your treatment How your treatment is given Special precautions that will need to be taken Possible side effects Discharge arrangements Whyam I having I131? Yourconsultant will have discussed the reasons whyyou have been advised to have I131, including what would happen ifyou chose notto have this treatment. You will also have been given some National patient information about this type of treatment (British Thyroid Association 2004). If you have anyfurther questions then you should ...

Differentiated Thyroid Cancer : Post-op & Long Term Management Apr 22, 2006 Mal Rajaraman Radiation Oncology Page 2 2 MR 2006 DTC: Post-op & Long Term Management Points to Consider Morbidity (recurrence) vs Mortality (survival) Recurrence Risk Stratification Roles of I-131 Therapy and External Beam Radiotherapy (EBRT) Long Term TSH Suppression (Dr. Imran) Proposed Surveillance Based on Risk Level Role of rhTSH Page 3 3 MR 2006 2 % of ca’s = 90% papillary / follicular (DTC) 0.2 % of all ca deaths ? : ? = 1 : 3 Thyroid Ca: Age-Standardized Incidence Rate per 100,000 (Canada 1991) Both Sexes Combined, All Ages, 1992-2001 4.77 - < 4.99 4.00 - < 4.40 4.99 - 6.95 4.40 - < 4.77 3.31 ...

This issue of Cancer Control focuses on thyroid cancer . The last time this journal devoted an issue to thyroid cancer was over 5 years ago. During that interval, sig- nificant advances have been made in the detection and management of thyroid cancer , and guidelines for the treatment of patients with thyroid nodules have been revised and updated. Thyroid cancer presents unique problems not seen in other cancers. Thyroid cancer comprises a relatively small portion of newly detected cancers. In 2006 in the United States,more than 30,000 new cases of thyroid cancers are expected out of 1,400,000 new cases of cancers at all sites. 1 Although cancer of the thyroid is relatively rare,thy- roid nodules, which are the primary indicator of develop- ing thyroid cancer , are quite common. Palpable thyroid nodules occur in approximately 5% of women and 1% of ...

April 2006, Vol. 13, No. 2 Cancer Control 111 Introduction Thyroid cancer is the most common endocrine malig- nancy and accounts for the majority of endocrine cancer - related deaths each year. 1,2 Accumulating evidence indicates that follicular cell-derived thyroid carcinomas constitute a biological continuum progressing from the highly curable well-differentiated thyroid carcinoma (WDTC) to the often fatal undifferentiated or anaplastic thyroid carcinoma (ATC). 3,4 Poorly differentiated thy- roid carcinoma (PDTC) and aggressive variants of WDTC, such as tall cell and columnar cell, frequently serve as intermediates in this progression model. 5,6 Genetic Considerations in Thyroid Cancer Kepal N. Patel, MD, and Bhuvanesh Singh, MD, PhD, FACS Background: Recent molecular studies have described a number ...

April 2006, Vol. 13, No. 2 Cancer Control 119 Introduction Malignant tumors of thyroid follicular cell origin have traditionally been classified as either well-differentiated thyroid carcinoma (WDTC),which is composed of pap- illary and follicular carcinoma, or undifferentiated/ anaplastic thyroid carcinoma (ATC). The vast majority of patients with WDTC have an excellent prognosis regardless of the types of treatment used, whereas patients with ATC uniformly have a poor prognosis. 1 There is growing evidence for the existence of a group of tumors that fall between WDTC and ATC in terms of both morphologic appearance and biologic behavior. Poorly Differentiated and Anaplastic Thyroid Cancer Kepal N. Patel, MD, and Ashok R. Shaha, MD, FACS Background: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic (undifferentiated) ...